
Drugmaker GSK (GlaxoSmithKline) has said it is “well positioned” to cope with any financial impact from changes to US tariff rules.
It came as the FTSE 100 giant revealed a rise in sales as weakness in its vaccine division was offset by growth in speciality medicines.